Summary
The disposition of 5-aminosalicylic acid (5-AS), the therapeutically active metabolite of sulphasalazine (SZ), has been studied in patients with active inflammatory bowel disease, in patients with biliary tract disease and post-operative T-tube drainage, and in healthy volunteers. Subjects were treated 3 times a day either with 5-AS 0.5 g suppositories and a slow-release preparation or with SZ 1 g tid (equivalent to 5-AS 1.14 g/day). Plasma and urine concentrations of 5-AS and its acetylated major metabolite (AcAS) were monitored during one dosing interval. In a cross-over trial in 5 patients with ulcerative colitis no difference, was found in the dose-corrected mean (± SD) steady state plasma levels (Css) of 5-AS and AcAS between treatment with 5-AS suppositories (0.10±0.07 and 0.50±0.20 µg/ml, respectively) and SZ (0.12±0.14 and 0.67±0.14 µg/ml, respectively). Urinary excretion of total AS (5-AS+AcAS), too, was similar (192±70 and 179±79 mg/day) with both forms of treatment. The oral slow-release form of 5-AS produced slightly higher Css in 5 patients with Crohn's disease (5-AS 0.21±0.22 µg/ml; AcAS 0.83±0.40 µg/ml) and in 5 healthy volunteers (5-AS 0.28±0.14 µg/ml; AcAS 1.10±0.43 µg/ml). Urinary recovery of total AS averaged 20±6% (patients) and 27±10% (volunteers). The cross-over trial in 7 patients with a biliary T-tube revealed that after single doses of 5-AS 1 g and SZ 2 g between 0.01% and 0.75% could be recovered in collected bile (85–500 ml/day) as total AS (traces of free 5-AS, and acetylated and glucuronidated 5-AS), indicating some enterohepatic circulation.
Similar content being viewed by others
References
Khan AK, Piris J, Truelove SC (1977) An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2: 892–895
Klotz U, Maier K, Fischer C, Heinkel K (1980) Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med 303: 1499–1502
van Hees PAM, Bakker JH, van Tongeren JHM (1980) Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 21: 632–635
Campieri M, Lanfranchi GA, Bazzocchi G, Brignola C, Corazza G, Cortini C, Michelini M, Labo G (1981) Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 2: 270–271
Das KM, Dubin R (1976) Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1: 406–425
Das KM, Eastwood MA, McManus JPA, Sircus W (1973) Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 289: 491–495
Singleton JW, Law DH, Kelly Jr ML, Makhjian HS, Sturdevant RAL (1979) National cooperative Crohn's disease study: Adverse reactions to study drugs. Gastroenterol 77: 870–882
Toovey S, Hudson E, Hendry WF, Levi AJ (1981) Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 22: 445–451
Miller B (1977) Wirkung und Nebenwirkung der Therapie mit Salizylazosulfapyridin. In: Kremer K, Kivelitz H (eds) Colitis ulcerosa. Georg Thieme, Stuttgart
Truelove SC (1981) The treatment of ulcerative colitis. Schweiz Med Wochenschr 111: 1342–1346
Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, Flachs H (1982) 5-Aminosalicylic acid in a slow-release preparation: Bioavailability, plasma level, and excretion in humans. Gastroenterology 83: 1062–1070
Fischer C, Maier K, Klotz U (1981) Simplified high pressure liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. J Chromatogr 225: 498–503
Fischer C, Maier K, Klotz U (1983) Specific measurement of 5-aminosalicylic acid and its acetylated metabolite in human bile. Br J Clin Pharmacol 15: 273–274
Pieniaszek HJ, Bates TR (1979) Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats. J Pharm Sci 68: 1323–1325
Willoughby CP, Piris J, Truelove SC (1980) The effect of topical N-acetyl-5-aminosalicylic acid. Scand J Gastroenterol 15: 715–719
Binder V, Halskov S, Hvidberg E, Kristensen E, Riis P, Tougaard L, Willumsen L (1981) A controlled study of 5-acetaminosalicylic acid (5-Ac-ASA) as enema in ulcerative colitis. Scand J Gastroenterol 16: 1122
Hansen ST (1981) Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high-performance liquid chromatography on dynamically modified silica. J Chromatogr 226: 504–509
Shaffii A, Chowdhury JR, Das KM (1982) Absorption, enterohepatic circulation, and excretion of 5-aminosalicylic acid in rats. Am J Gastroenterol 77: 297–299
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fischer, C., Maier, K., Stumpf, E. et al. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur J Clin Pharmacol 25, 511–515 (1983). https://doi.org/10.1007/BF00542120
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542120